DPHARMA 7148 DUOPHARMA BIOTECH BERHAD | Revenue and Profit Record High (Q1FY2023)
The pharmaceutical industry plays a crucial role as an integral part of the global healthcare system. With the increasing global population and longer life expectancy, the demand for medications is also on the rise. Particularly in developing countries, improvements in healthcare standards and an aging population are driving the demand and reliance on pharmaceuticals. According to a survey conducted by the Pharmaceutical Association of Malaysia (PhAMA), the pharmaceutical industry contributed RM6.00 billion to Malaysia's Gross Domestic Product (GDP), and it is expected to contribute another RM10.00 billion by 2024.
A few days ago, Duopharma Biotech Berhad (DPHARMA, 7148), a renowned Malaysian pharmaceutical company, announced impressive performance results with record-high revenue and profit for the first quarter.
As a reference, DPHARMA is a pharmaceutical company equipped with advanced medical technology. It was established in 1978 and went public in 2002. The company operates three research and manufacturing facilities in the Klang Valley of Malaysia, located in Bangi, Klang, and Glenmarie, Shah Alam. Additionally, DPHARMA has subsidiaries in Singapore, the Philippines, and Indonesia. Not to mention that the company also collaborates with the Indian pharmaceutical company Biocon Limited.
DPHARMA's main business involves the research, development, and manufacturing of generic drugs and healthcare products, which are then sold to private and government healthcare centres. Based on the 2022 annual report, approximately 57.29% of the revenue comes from private healthcare centres, while the remaining 42.71% comes from government or public healthcare centres. The company has a broad market presence and has exported its products to 31 countries. However, Malaysia remains DPHARMA's primary sales market, accounting for approximately 93.99% of the revenue in the fiscal year 2022.
Now, let's delve into the latest performance announced by DPHARMA for Q1FY2023.
Revenue Comparison (YoY +7.81%, QoQ +31.92%)
As of March 31, 2023, the company achieved approximately RM200.47 million in revenue, representing an increase of approximately RM14.54 million or 7.81% compared to the same period last year, when revenue was RM185.94 million. This growth is primarily attributed to an increase in sales volume of prescription drugs.
Out of the RM200.47 million revenue, approximately RM188.73 million came from Malaysian customers, while the remaining RM11.74 million came from overseas sales.
Compared to the previous quarter, the company's revenue significantly rose by approximately RM48.52 million or 31.92%, primarily driven by increased demand for medications from the Ministry of Health. It is worth noting that the previous quarter (4QFY22) usually experiences lower purchases from the Ministry of Health due to the year-end accounting period. Therefore, the orders from the Ministry of Health witnessed a significant increase this quarter.
Net Profit Comparison (YoY +11.53%, QoQ +31.87%)
Driven by the overall robust revenue performance, DPHARMA achieved a net profit of approximately RM22.63 million this quarter, representing a year-on-year and quarter-on-quarter growth of approximately 11.53% and 31.87%, respectively.
However, the increase in electricity costs and labor expenses has affected the company's profitability to some extent. It is anticipated that the company may offset the rising operating costs by increasing product selling prices in the future.
Outlook
The company is poised to benefit from patients returning to hospitals, increased government allocations to the Ministry of Health, and a gradual stabilization of active pharmaceutical ingredient prices. Additionally, DPHARMA's introduction of pure plant-based healthcare products such as Champs and Flavettes will be advantageous for the company's future profit growth.
It is worth mentioning that the company currently holds a three-year contract valued at RM375.00 million, which involves supplying reconstituted insulin formulations (Insugen-Insulin Recombinant Human Formulations) to the Ministry of Health until April 2025. Furthermore, the contracts with government hospitals and clinics for the supply of both pharmaceutical and non-pharmaceutical products have been extended until June 30, 2023.
In addition, Malaysia plans to open five public hospitals and 19 private hospitals in the next three years, further enhancing the company's growth potential.
Given the high growth potential and the current price-to-earnings ratio (P/E) of 19.52 times, what are your thoughts on DPHARMA?
#DPHARMA
https://xifu.my/OpinionsComment.aspx?BID=B02436230PBAA0EC
Singapore Investment
-
-
-
-
-
-
-
-
-
-
-
Decumulate To Accumulate9 hours ago
-
-
-
-
Trading Journal As Of 14 Feb 202518 hours ago
-
Cory Diary : Insurance Policy Returns19 hours ago
-
-
-
PARAGON REIT FY2024 Financial Results23 hours ago
-
-
-
-
-
-
-
-
-
-
Finance Investment Movement 542 days ago
-
Net Worth Update Feb 20252 days ago
-
-
-
-
-
-
-
A Chinese New Year trip back home4 days ago
-
-
-
-
-
-
-
-
-
-
Sold SCCO1 week ago
-
-
-
-
-
Harnessing Volatility as an Asset Class1 week ago
-
-
-
Spending for Jan 2025: Hit $8001 week ago
-
Jan 2025 Portfolio2 weeks ago
-
-
-
Portfolio Summary for January 20252 weeks ago
-
-
Jan 2025 Investment Update2 weeks ago
-
-
Portfolio -- Jan 20252 weeks ago
-
-
-
-
Portfolio (Jan 30, 2025)2 weeks ago
-
LHN share price rocketed 270%!2 weeks ago
-
ETF vs Mutual Fund: Which is Better?3 weeks ago
-
UAE Golden Visa: The Ultimate Guide3 weeks ago
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
4Q 2024 Investment Strategy Update1 month ago
-
Top 10 Highlights of 20241 month ago
-
-
-
Why do I question about life?1 month ago
-
-
-
-
-
Reflections for year 20242 months ago
-
-
My Palantir Regret2 months ago
-
-
2023 Trading Recap – $11,000 in profit!2 months ago
-
-
-
Union Square Residences3 months ago
-
-
-
China boom?4 months ago
-
-
STI ETF4 months ago
-
-
-
-
Unibet Casino Bonus Codes 20245 months ago
-
-
-
-
-
-
-
Monthly IBKR Update – June 20247 months ago
-
-
-
-
-
-
-
Breakthroughs in portfolio :)8 months ago
-
-
-
Feb 2024 Expenditure10 months ago
-
-
APAC Markets: First Trends in 202411 months ago
-
-
-
-
-
Monthly Summary of November 20231 year ago
-
Migration of website1 year ago
-
-
-
-
-
-
-
-
-
-
A New Light1 year ago
-
-
-
-
-
-
2022 Thoughts, Hello 2023!2 years ago
-
Series of Defaults for Maple Finance2 years ago
-
Takeaways from “Sea Change”2 years ago
-
Greed is Coming Back2 years ago
-
-
Investing is Easy2 years ago
-
-
-
-
-
-
-
What is Overemployment2 years ago
-
Terra Hill Condo (former Flynn Park)2 years ago
-
Alibaba VS Tencent: The Battle Royale2 years ago
-
-
-
-
-
-
-
-
-
-
-
-